论文部分内容阅读
目的分离鉴定芪苈强心胶囊活性部位中的成分。方法采用溶剂提取和大孔吸附树脂柱色谱的方法分离芪苈强心胶囊的不同部位,通过活性筛选确定有效部位,利用HPLC-PDA/ELSD进行活性部位的指纹图谱分析,并通过柱色谱对其中的化学成分进行分离纯化,根据所得化合物的核磁、质谱数据及与对照品对比鉴定化合物的结构。结果 W-4和E-4为芪苈强心胶囊的强心、利尿及扩血管等活性部位,建立了其HPLC-PDA/ELSD的指纹图谱,并从中分离鉴定了11个化合物,分别为毛蕊异黄酮-7-O-β-D-葡萄糖苷(1)、人参皂苷Re(2)、人参皂苷Rg1(3)、杠柳苷G(4)、人参皂苷Rf(5)、人参皂苷Rb1(6)、人参皂苷Rc(7)、人参皂苷Rb2(8)、丹酚酸B(9)、山柰酚-3-O-芸香糖苷(10)和丹酚酸A(11)。结论明确了芪苈强心胶囊强心、利尿及扩血管的活性部位,11个化合物均为首次从芪苈强心胶囊中得到的化合物,这些化合物在活性部位中的指认为提供胶囊的质量标准奠定了基础,同时为阐述芪苈强心胶囊的药效物质打下了基础。
Objective To isolate and identify the active components of Qiliqiangxin capsule. Methods Different fractions of Qiliqiangxin capsule were isolated by solvent extraction and macroporous resin column chromatography. Active fractions were identified by active screening. The fingerprints of active fractions were analyzed by HPLC-PDA / ELSD. Of the chemical constituents were isolated and purified, according to the resulting compounds NMR, MS data and compared with the control to identify the structure of the compound. Results W-4 and E-4 were the active sites of cardiac, diuretic and vasodilator of Qiliqiangxinxin. HPLC-PDA / ELSD fingerprinting was established and 11 compounds were isolated from them, (4), ginsenoside Rf (5), ginsenoside Rb 1 (6), ginsenoside Re (2), ginsenoside Rg 1 ), Ginsenoside Rc (7), ginsenoside Rb2 (8), salvianolic acid B (9), kaempferol-3-O-rutinoside (10) and salvianolic acid A (11). CONCLUSIONS: The cardiac, diuretic and vasodilator active sites in Qiliqiangxin Capsule were identified. All the 11 compounds were obtained from Qiliqiangxin Capsules for the first time. These compounds were identified in the active site as the quality standard for capsules Laid the foundation, at the same time to elaborate Qi Qiang Qiangxin capsule laid the foundation for the efficacy of substances.